ABVC BioPharma, Inc. (ABVC): Price and Financial Metrics
ABVC Price/Volume Stats
| Current price | $1.54 | 52-week high | $1.81 |
| Prev. close | $1.50 | 52-week low | $0.40 |
| Day low | $1.48 | Volume | 375,200 |
| Day high | $1.65 | Avg. volume | 492,399 |
| 50-day MA | $1.15 | Dividend yield | N/A |
| 200-day MA | $0.73 | Market Cap | 26.15M |
ABVC Stock Price Chart Interactive Chart >
ABVC BioPharma, Inc. (ABVC) Company Bio
American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.
ABVC Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABVC Price Returns
| 1-mo | 16.67% |
| 3-mo | 141.15% |
| 6-mo | 207.39% |
| 1-year | 98.20% |
| 3-year | -91.94% |
| 5-year | -94.87% |
| YTD | 161.02% |
| 2024 | -49.14% |
| 2023 | -81.44% |
| 2022 | -81.56% |
| 2021 | -33.53% |
| 2020 | 16.70% |